Fc fragment with antigen-binding (Fcab) is a novel construct which can be selected to recognize specifically a wide variety of target proteins. We describe the selection and affinity maturation of Fcab clones targeting VEGF, an important pro-angiogenesis factor. To investigate the extent of engineering permissible to Fcabs we applied targeted mutagenesis to all three C-terminal loop structures and the C-terminus of the C H 3 domain to isolate high-affinity binders by directed evolution and yeast display. The matured clone, CT6, binds to VEGF with low nanomolar affinity and inhibits VEGFstimulated proliferation of human umbilical vein endothelial cells in vitro. Molecular dynamics simulations were performed to address flexibility of the molecular structure of CT6 and to approximate a structural ensemble in aqueous solution. Significantly higher RMSF levels of CT6 in comparison to wild-type Fc were limited to the elongated CD-loop in the C H 3 domain, while the overall structural integrity was retained. This allowed the Fcab to replace the Fc portion of a mAb, in which both the C H 3 and Fab are capable of antigen engagement: a construct called mAb 2 was assembled with CT6 and the Fab of bevacizumab. This bispecific molecule showed more potent antagonistic activity than bevacizumab in vitro. Further evaluation for the potential of the CT6 Fcab in targeted therapy is warranted due to the possibility of being combined with other therapeutically meaningful targets.
Introduction
Antibodies are uniquely suited for human immune defense due to the ability of highly specific antigen recognition brought about by a composite binding surface formed by the variable regions in the Fab domains, and the innate ability to evoke effector functions mediated by the constant domains. The latter also endow the molecules with long half-lives in vivo through the binding to neonatal Fc receptor (FcRn) (Brambell et al., 1964; Ghetie et al., 1996; Dickinson et al., 1999) . The inherent stability of these molecules has contributed to the successful development of many antibody-based therapeutic agents. The constant domain of a monoclonal antibody (mAb) has been the focus of intense engineering efforts. Besides modifications that enhance or temper interactions with Fc receptors, novel binding sites mediating specific antigen recognition have been successfully engineered into constant domains (Wozniak-Knopp et al., 2010; Ying et al., 2014) , which underlines the amenability of immunoglobulin subunits for the design of novel properties.
Each of the antibody domains displays the Greek key β-barrel topology composed in the case of constant domains of seven β-strands (Feige and Buchner, 2014) . Folding of an Ig domain is initiated by a nucleus composed of IgG strands B, C, E and F around which the scaffold forms (Williams and Barclay, 1988) . At the N-terminal end, three loops connect the β-strands and at the C-terminal end two small helices connect strands A to B and E to F. The helices are evolutionarily highly conserved, and the one between strands E and F often contains a hydrophobic or aromatic amino acid that participates in the formation of the hydrophobic core of the immunoglobulin domain (Aurora et al., 1997) . The stability of an Fc fragment is dependent on the stabilizing interactions of C H 2 and C H 3 domains (Harris et al., 1997) , derived from~100Å 2 contact surface mediated by eight amino acid residues of the C H 2 and 13 residues of the C H 3 domain, respectively (Teplyakov et al., 2013) . The position of the C H 2 domain is affected by the pivoting motion of Leu251 (EU numbering), centered in the pocket formed by the residues Met428, His429, Glu430, and His435 of the C H 3 domain (Teplyakov et al., 2013) . A traditional scaffold approach was used in the seminal design of Fc fragment with antigen-binding (Fcab): with the aim of minimizing changes in the overall structure of the Fc fragment, only the residues of the C-terminal loops AB and EF of the C H 3 domain with solvent-accessible side chains were randomized, as these loops are positioned in an immediate vicinity and able to form a contiguous binding surface (Fig. 1A) . The new binding surfaces do not overlap with those engaging with Fc receptors or protein A and such a design allows an Fcab to retain many of the key structural and functional properties of the wild-type Fc fragment: potential of evoking effector functions, long half-life in vivo, and being purified by protein A resins (Wozniak-Knopp et al., 2010) . Fcabs with high affinity and potency have been described with as few as nine mutations within two structural loops (Leung et al., 2015) . Once primary binder clones have been isolated against a target, directed evolution such as coupling mutagenesis with various selection schemes can be performed to further stabilize the molecule (Traxlmayr et al., 2013) or to fine tune its antigen binding mode . Here we set out to investigate whether other structural elements of the C H 3 domain are equally permissible to mutagenesis to further improve the potency of an Fcab in antigen engagement.
We chose vascular endothelial growth factor (VEGF) as a model target for our studies. VEGF is a key pro-angiogenesis factor which potently stimulates proliferation of endothelial cells. It plays an important role in normal development, but also in disease states such as the growth of solid tumors (Veeravagu et al., 2007) , rheumatoid arthritis (Azizi et al., 2014) , and ocular neovascularization (Campochiaro et al., 2013) . Application of antibodies and Fab fragments that antagonize VEGF-dependent cell proliferation by preventing the ligand from binding to VEGF receptor-2 (VEGFR-2) is clinically effective in the treatment of cancer and other disease states such as age-related macular degeneration (AMD) (Stuart et al., 2015) and diabetic rhetinopathy (Nicholson and Schachat, 2010) . A number of non-antibody scaffolds with antagonistic activity have also emerged as potential anti-VEGF therapies, among them an ankyrin based scaffold (Querques et al., 2015) and a lipocalin based scaffold (Mross et al., 2013) . Despite these advances, medical needs remain unmet due to resistance resulting from incomplete blockage of the VEGF signaling, the existence of redundant pathways, or the up-regulation of escape pathways. Combination therapies as well as bispecific molecules containing a VEGF-targeting moiety may be able to address some of these resistance mechanisms (Huang and Carbone, 2015) . In obtaining a high-affinity VEGFblocking Fcab, we could potentially create such a bispecific antibody molecule by incorporating the Fcab into an antibody targeting another biologically relevant specificity.
Materials and methods

Construction and selection of primary Fcab library
All oligonucleotide sequences used for library construction are given in Supplementary Figure 1 available at PEDS online. The naïve Fcab library was constructed using oligonucleotides abmut2lr and upplus0 that allow gap-repair driven homologous recombination into the vector pYD1dXFcdem, which was constructed from pYD1 with deleted XhoI site to which the sequence of human IgG1 was cloned and the sequence of the C H 3 domain excised between naturally occurring XmaI and NsiI sites and replaced with two oligonucleotides encoding BsmBI sites, bsmecol1 and bsmecou2 (Supplementary Figure 1 available at PEDS online). The PCR library fragment and BsmBI-restricted vector fragment were transformed into EBY100 cells using the high-efficiency LiAc/single-strand carrier DNA/PEG method (Gietz and Schiestl, 2007) , selected in 500 ml SD-CAA (20 g/L glucose, 6.7 g/L yeast nitrogen base without amino acids, 5.4 g/L Na 2 HPO 4 , 8.6 g/L NaH 2 PO 4 .H 2 O and 10 g/L casamino acids) and aliquots were plated to determine library diversity. Subsequent libraries were constructed with similar methods. The selection, cultivation and induction of yeast colonies were performed according to standard protocols (Chao et al., 2006) . The library constructed in EBY100 was 5 × 10 8 in size and of 61% correctness.
Induced yeast cells were stained with 500 nM biotinylated VEGF and with anti-Xpress antibody (Thermo Fisher Scientific) for normalization. Sorting was performed on BD FACSARIA TM I sorter. In the first sorting round, 5 × 10 8 yeast cells were processed and in the following sorting rounds 100-times the output of the previous sorting round were processed. In all four sorting rounds the top 1% of the double positive population was collected. After sorting, single clones were tested for antigen binding at 500 nM concentration. Plasmids encoding Fcab sequences were isolated using Zymoprep II (Zymoresearch), amplified in E. coli TOP10 cells and sequenced or used for subcloning.
Affinity maturation campaigns
Affinity maturation libraries were constructed using spiked oligonucleotides and deletion variants of the vector pYD1: pYD1dXFcdem described in previous section and pYD1dXFcCD for the modifications of CD-loop, which was constructed by an introduction of a SacI site with oligonucleotides cdsac1 and cdsac2, restricted with SacI and NsiI and sealed with oligonucleotides cdstuf1 and cdstuf2 (Supplementary Fig. 1 available at PEDS online). For modifications of C-terminus, C H 3 domain was excised and vector backbone used for library construction. Spiked oligonucleotides were designed with a ratio of nucleotides 85:5:5:5 for the first two bases, preserving 85% of the original nucleotide, and 50:50 for the third base of the triplet (Supplementary Fig. 1 available at PEDS online). The constructed libraries were between 2 × 10 7 and 1 × 10 8 in size. Sorting was performed using biotin-labeled antigen at a half-logarithm lower than the threshold concentration determined with the titration of the original clone or best binder. Normalization was performed with anti-Xpress antibody (Thermo Fisher Scientific) or anti-C H 2 antibody (Bio-Rad). In a series of selection campaigns, schematically presented in Fig. 2 , the top 0.1% of the positive population was collected for consecutive three to four sorting rounds. In the first round, the input of the selection was five-times the library size and in the following rounds 100-times the output of the previous sorting round. Thirty to fifty selected clones were screened for antigen binding at a sub-threshold antigen concentration used for sorting.
Clones showing improved binding in respect to the parental clone were sequenced.
Expression and purification of Fcabs as soluble proteins
For characterization in soluble form, full length C H 2-C H 3 sequences were cloned into pPICZalphaA and Pichia pastoris X33 (Thermo Fisher Scientific) was used as a host for methanol-induced expression of Fc fragments. After electroporation of SacI-linearized expression plasmid, the transformed colonies were isolated on zeocin-containing medium, cultured in YPG and induced with 1% methanol, following standard protocols (Cregg and Cregg, 2007) 
ELISA-based methods
Purified Fcab proteins (see below) or supernatants of Fcab yeastdisplay cultures were used in ELISA-based affinity ranking. To obtain supernatants, a set of 96 single colonies resulting from the last sorting round was inoculated into 2 ml SD-CAA medium in deep well plates (Thermo Fisher Scientific) and grown overnight at 30°C. Cells were pelleted by centrifugation at 3000g for 10 min. The pellets were resuspended in 2 ml of SG/R-CAA (20 g/L galactose, 10g/L raffinose, 6.7 g/L yeast nitrogen base without amino acids, 5.4 g/L Na 2 HPO 4 , 8.6 g/L NaH 2 PO 4 .H 2 O and 10 g/L casamino acids) and induced overnight at 37°C. The samples were harvested at 3500 g for 20 min. The supernatants containing Fcabs or purified Fcab samples in 3-fold serial dilutions in PBS were loaded in microtiter wells, which had previously been coated with 5 μg/ml VEGF 165 in PBS for 1 h at room temperature (RT) and blocked with 4% bovine serum albumin in PBS for 1 h at RT with continuous shaking. The plates were washed three times with PBS prior to the addition of 100 μl of anti-human Fc-HRP conjugate (Sigma-Aldrich) and incubated for 45 min. The wells were washed three times, and 100 μl of the developing solution TMB (Sigma-Aldrich) was added to each well. After 30 min, 100 μl stop solution (30% H 2 SO 4 ) was added to each well and the absorbance at 450 nM and background at 620 nM was measured with a Tecan Sunrise spectrophotometer. To identify Fcabs that share a VEGF-binding epitope with bevacizumab, Fcabs were first incubated with 1 μg/ml biotinylated VEGF for 1 h at RT. ELISA plates were coated with 10 μg/ml bevacizumab and blocked as described above. Test mixes of Fcabs and VEGF were incubated in microtiter wells for 1 h at RT, and VEGF that had been captured by bevacizumab was detected with streptavidin-HRP. The reaction was developed, stopped and read as described above. The signal obtained with wild-type Fc as mock inhibitor at the concentration corresponding to the highest concentration of Fcab used in the assay was considered 100% value.
To determine the ability of competition for VEGF with VEGFR-2 in vitro, Fcab CT6 was first incubated with 4 μg/ml biotinylated VEGF for 1 h at RT. 1 μg/ml VEGFR-2-Fc (R&D Systems) was immobilized on ELISA plates pre-coated with 10 μg/ml anti-human Fc (Sigma-Aldrich). The mix of Fcabs and VEGF was incubated in microtiter wells for 1 h at RT, and VEGF that had been captured by VEGFR-2 was detected with streptavidin-HRP. The reaction was developed, stopped and read as described above.
Affinity measurements
Biolayer interferometry
The relative affinity constant of each Fcab against VEGF was determined by biolayer interferometry (BLI). The VEGF antigen was biotinylated using NHS-LC-LC-Biotin (Thermo Fisher Scientific) at a 1.5:1 molar ratio of biotin to VEGF dimer for 1 h at RT, followed by overnight dialysis against PBS at 4°C. Binding assays were performed with an Octet system (Pall Forte Bio Europe) and Forte Bio Acquisition Software in 96-well-microtiter plates at 30°C with orbital sensor agitation of 1000 rpm. Biotinylated VEGF (10 μg/ml) was loaded onto Streptavidin (SA) biosensors, a baseline was established in PBS buffer supplemented with 10% (v/v) 10× Kinetics buffer (Pall Forte Bio Europe) followed by association at varying analyte concentrations. Serial dilutions were made to produce 200 μl of 2-fold serial dilutions of Fcabs in appropriate wells of the assay plate, starting from 100 nM. Antigen-coated sensors were placed in six different concentrations of Fcabs for 300 s, during which the antibodies were bound to the antigen coupled to the sensor. Sensors were rinsed in 1× Kinetics Buffer for 600-900 s. When using inverted outlay, antihuman Fc (ahFc) sensors were used to immobilize 20 μg/ml Fcab and then immersed into six graded concentrations of VEGF, starting from 500 nM. The assay was run under the same parameters as described, apart from a longer association time of 600 s. Double reference was recorded in 1× Kinetics Buffer and was subtracted from all measurements. Octet Analysis Software version 6.4 was used for automatic data processing. Biosensor data were fit using a 1:1 binding model.
For FcRn binding analysis, 20 μg/ml biotinylated FcRn (Immunitrack AS) was loaded on streptavidin tips. Binding of BE and CT6/BE in 2-fold dilution series starting from 500 nM was examined in PBS, pH 6.0 supplemented with 1× Kinetics buffer for 300 s and dissociation was measured for 900 s. To examine pH-dependent binding, dissociation buffer used was PBS with 1× Kinetics buffer, pH 7.4. Biosensor data were fit using a heterogenous ligand binding model.
Isothermal titration calorimetry
Experiments were performed using a VP-ITC instrument from Microcal. Injections of 10 μl of Fcab solution were added from a computer-controlled microsyringe at an interval of 6 min into the sample solution of VEGF (cell volume 1.42 ml) with stirring at 307 rpm. The concentration of the VEGF was 1.2 μM, and the Fcab was 20 μM. The experimental data were fitted to a theoretical titration curve using software supplied by Microcal, with ΔH (binding enthalpy), ΔS (entropy), and n (number of binding sites), as adjustable parameters. Thermodynamic parameters were calculated from the Gibbs free energy equation, ΔG = ΔH -TΔS, where ΔG, ΔH, and ΔS are the changes in free energy, enthalpy, and entropy of binding, respectively. T is the absolute temperature.
Biophysical characterization
Differential scanning calorimetry Differential scanning calorimetry (DSC) experiments were performed using an automated CAP VP-DSC MicroCalorimeter (MicroCal), using 5 μM protein solution, diluted in PBS at pH 7.4. The heating was performed from 20°C to 110°C at a rate of 1°C/min. Fitting was performed with MicroCal Origin for DSC using the nontwo-state transition mechanism.
CD spectroscopy
The circular dichroism (CD) spectra were measured on a Chirascan spectropolarimeter (Applied Photophysics). A 1 mm quartz cuvette was used for far-UV spectra measurements. The proteins were diluted in PBS to a concentration of 267 μg/ml. The CD spectra of the buffer solutions were subtracted from the sample spectra.
Size-exclusion HPLC Shimadzu LC-20A Prominence system equipped with a diode array detector and a refractive index detector was used to perform sizeexclusion HPLC (SEC-HPLC) with a TSK G3000 SWXL (7.8 × 30 mm) column. The mobile-phase buffer used was PBS with 200 mM NaCl. Chromatography was conducted with a constant flow rate of 1 ml/min. A total of 25 μg protein at~1 mg/ml were loaded on the column for analysis.
Serum stability
The Fc fusion proteins were diluted to a concentration of 333 nM in 50% murine serum (Sigma-Aldrich) and incubated for 0, 1, 3 or 7 days at 37°C and then stored at −80°C. The protein integrity was determined via a VEGF-binding ELISA as described above in the ELISA-based methods section. Standard curve was established with purified BE or CT6/BE and fit with four-parameter method with SigmaPlot 13.0. OD values at 450/620 nm were compared.
HUVEC proliferation assay
TERT-immortalized HUVEC cells were seeded in complete EndoUP2 medium (Evercyte) at a split ratio of 1:4 into a gelatincoated 96-well plate and cultured for 48 h at 37°C in humidified atmosphere with 5% CO 2 . Prior to the experiment, the cells were starved of VEGF for 48 h in basal medium without VEGF. Test protein preparations in graded concentrations were incubated with basal medium supplemented with VEGF to a final concentration of 15 ng/ml for 2 h at 37°C. Subsequently, cell culture medium was exchanged for the pre-incubated mixture. After 72 h cultivation, the proliferation of HUVEC cells was determined using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. Sample sizes were n = 2 for the incubation with medium alone and n = 4 for all other measurements. The inhibition of CT6/ BE and BE were compared for significance using Student's T-test.
Structure modeling and molecular dynamics simulation
A homology model of the single mutated C H 3 domain of CT6 starting with residue Gln342 was computed using SWISS-MODEL and a wild-type crystal structure of human IgG1 Fc (PDB-ID 1OQO, chain A) as template. Loops and the C-terminal strand containing mutations were then ab initio remodeled sequentially using the NGK algorithm implemented in the Rosetta Protein Modeling Suite (version 3.5) to partially account for eventual biases introduced by the secondary loop structure and the missing CD-loop insertion in the template structure. Since the template structure lacks the last three C-terminal residues, those residues were modeled using the NGK algorithm prior to homology modeling. For this approach five virtual alanine residues were added C-terminally to allow flexible sampling. Dimeric CT6 C H 3 structures were constructed by superposition with the dimeric wild-type C H 3 structure.
Molecular dynamics (MD) simulations were performed using GROMACS 5.0 (Pronk et al., 2013) after solvation in simple-pointcharge (SPC) water (Berendsen et al., 1981) in a rhombic dodecahedron box with a minimum protein-to-wall distance of 1 nm and 3D periodic boundary conditions. Sodium ions were added until a net charge of zero was reached. Force field parameters were taken from the GROMOS 54A7 force field (Schmid et al., 2011) . After initial energy minimization the systems were equilibrated for 100 ps at a constant temperature of 300 K after randomly assigning velocities from a Maxwell-Boltzmann distribution at 300 K using a modified weakcoupling thermostat (Berendsen et al., 1984; Bussi et al., 2007) with a relaxation time of 0.1 ps. Subsequent NPT equilibration was done for 100 ps using isotropic pressure scaling and a Parrinello-Rahman barostat (Parrinello and Rahman, 1981; Nose and Klein, 1983 ) with a coupling time constant of 0.5 ps, a reference pressure of 1 bar and an isothermal compressibility of 4.575 × 10 −5 bar −1
. Position restraints with a force constant of 1000 kJ mol −1 nm −1 were applied to protein atoms during equilibration. Simulations were then extended for 300 ns without position restraints. A leap-frog integrator (Hockney, 1970) with a timestep of two fs was used. The center of mass translation and rotation was removed every 100 steps. All covalent bonds were constrained using the Linear Constraint Solver (LINCS) algorithm (Hess et al., 1997) and neighbor searching was realized using Verlet lists (Verlet, 1967 ) with a buffer tolerance (Pall and Hess, 2013) . A non-bonded interaction cutoff of 1.4 nm was applied and a reaction field contribution (Tironi et al., 1995) with a relative permittivity of 61 beyond the cutoff sphere (Heinz et al., 2001 ) was added for treatment of electrostatic interactions. Furthermore, a long range dispersion correction for energy and pressure was employed. Three different dimeric models (wild-type C H 3, the CT6 homology model and the CT6 ab initio loop model) were independently simulated after removal of the five C-terminal virtual Ala residues two times each. Snapshots were taken every 2 ps. All simulations were performed on local workstations using GPU acceleration.
Results
Potential target interaction positions
Initial design and selections of the naïve library Residues with high solvent accessible surface area were identified at the C-terminal tip of the molecule from the crystallography structures of a wild type IgG1 Fc fragment (1HZH.pdb and 1OQO.pdb). These are comprised of the small helical stretches formed by the residues 358-362 in the AB-loop and residues 413-418 in the EF-loop, as well as the extension of the EF-loop from residues 419 to 422 which is capped by residue Phe423 whose aromatic phenyl group submerges back into the molecule forming part of the folding nucleus of the immunoglobulin domain. For the initial library, the residues 358-362, 413-415 and 418-422 were chosen for randomization. Residues Arg416 and Trp417 were not mutated, as Arg416 has little solvent exposure and forms a salt bridge with Glu388 while the side chain of Trp417 is completely buried and contributes to the hydrophobic core of the molecule. Collectively, the identified solvent exposed surface was contiguous on a monomeric C H 3 domain and of~100 Å 2 in size (Fig. 1) .
Yeast display libraries were made based on a fusion construct of human IgG1 Fc and Aga2p, in which the mutable residues identified above were fully randomized using NNK codons. The proteins were displayed on the surface of S. cerevisiae EBY100 and binders of micromolar affinity were selected (Table I ). Sequence analysis revealed that one clone, V2, accounted for 43.5% of all binders. All binders shared a common motive on the positions 413-415, composed of a residue with a phenyl ring at the position 414 and one or two Pro at 413 and 415. These clones were further tested for their ability to compete with bevacizumab for VEGF binding, as well as their elution profile when subjected to SEC-HPLC (Supplementary Figure 2A available at PEDS online). Clone V9 was found to be both active in the competition assay with bevacizumab and to show a wild-type-like SEC-HPLC profile, and was thus chosen for affinity 
Percent occurrence denotes the frequency of the clone in the pool after the fourth sorting round. The activity of the clone at the indicated concentration in competition assay with bevacizumab is given in % signal obtained with mock competitor, the wild-type (wt) Fc. maturation (selection scheme shown in Fig. 2 ) to improve its 12 μM affinity to the antigen.
To compensate for the relatively small size of the naïve library of 5 × 10 8 independent members, parsimonious mutagenesis was employed to increase diversity. Fifteen percent of the bases on the first and the second position of the codon triplet were randomly mutated within the putative binding sequence to exchange~27% of the amino acids at each position involved. After the selections of the maturation yeast-display library L1 of 7 × 10 7 independent members with a sub-threshold concentration of 1 nM biotinylated VEGF, binders that exhibited a tighter antigen binding on the yeast surface as well as in the soluble form were selected (Table II) . Several mutations were identified to be common to these improved clones ( Fig. 3 and Table II ). The most common mutations observed in the AB-loop were Val360Phe, Ser359Ala and Gln362Asn. The affinity of these improved clones was determined to be in the range of 1460-146 nM, which was a significant improvement over that of the primary binders. The SEC-HPLC profiles of these Fcabs showed that most were free of aggregate with single symmetrical peaks (Supplementary Figure 2B available at PEDS online). The most prominent mutation identified in the EF-loop as a result of affinity maturation was Thr419Met. Arg416 and Trp417 were also subjected to randomization. In the clones where the improved antigen binding could be confirmed in soluble format, substitution of Arg416 to Ser or Lys was observed in some, while Trp417 was retained in all.
Involvement of CD-loop in antigen binding
The CD-loop is unmodified in the basic design of the Fcab library due to the spatial distance of the loop to the putative antigen binding surface formed by the AB-and EF-loops. Nevertheless, we hypothesized that engaging the CD-loop in the binding surface may potentially increase the number of contacts with the antigen and thus lead to an Fcab with higher affinity. Structurally, this loop is best described as a β-hairpin, and residues Ser383 and Gly385 are required to provide a small phi-angle to allow its formation. To test this hypothesis, we constructed a yeast-display library L2A where residues Ser383 to Gln386 of the V9 clone were subjected to total randomization, which was confirmed by sample sequencing. The output clones were selected for their ability to bind 1 nM biotinylated VEGF (sub-threshold concentration for the parental clone) and an anti-C H 2-antibody that has been previously used successfully as a proxy probe for the folding state of the C H 3 domain (Traxlmayr et al., 2012) . The percentage of anti-C H 2-positive clones amounted to 23.3% when the libraries were induced at 20°C and 12.2% when the induction was performed at 37°C. Enrichment of antigen binding clones was achieved after three selection rounds. The prevalent clone L2A_5 with antigen-binding affinity of 4 μM, a 3-fold improvement over the parental clone, showed the Gly383-Leu384-Asp385-Gly386 motif in the CD-loop. The same motif was also found in~60% of all sequences of the other improved clones (Table II) . In addition, an aspartic acid residue could be found at position 384 or 385 in all the improved clones. The presence of two glycine residues, one at position 383 and one at either 385 or 386, is consistent with the hypothetical structural requirements for small-phiresidues at these positions.
Identifying a site tolerant to insertion
One way to circumvent the limited amenability of the CD-loop for modification could be the insertion of additional amino acids residues in the proximity so that improved contact to the antigen may be achieved. A biomimetic approach was used to identify tolerable CDloop insertions. The comparison of the sequences collected in the IMGT database revealed several interspecies discrepancies between residue 385 and residue 390 in the CD-loop (EU numbering), which form contacts with amino acids in β-strands B and E, respectively. Specifically, four residues can be found in human IgG and six in Sus scrofa and in Chondrichtyes IgG. Pro387 remained unchanged because of its role as a kink-forming amino acid. Therefore oligonucleotides were designed to amplify separately the pool of AB-loop sequences and EF-loop sequences that were selected after the affinity maturation campaign of the clone V9. The amplicon containing the EF-loop sequences included randomized residues Glu388 and Asn389 as well as a primer-imposed insertion of five random amino acid residues at this position (Supplementary Figure 1 available at PEDS online). Antigen binding could be detected for all of the library clones (L2B) under the normal conditions of induction at 20°C, and for over 50% of the clones under the stress conditions of induction at 37°C. After three rounds of antigen selection of the library, Fcabs were produced from the selected clones, and showed further improvement in affinity with K D of 75-160 nM. The SEC-HPLC profiles of these Fcabs showed well behaved proteins with less than 5% of aggregates (Supplementary Figure 2D available at PEDS online), suggesting that the insertions in the CD-loop were well tolerated. The mutation Gln362Asn in the clones L2B_1, 14 and 40 created a potential Nlinked glycosylation site, and N-linked glycosylation was evident in some of these clones based on their altered migration pattern in SDS-PAGE corresponding to a molecular size that is~5 kDa larger than that of wild-type Fc (Supplementary Figure 3A available at PEDS online). However, abrogating the glycosylation site by mutating Asn362 to Ser in such clones did not affect the antigen binding (Supplementary Figure 3B available at PEDS online). Fcab clone L2B_14 with an antigen-binding affinity of 75 nM was chosen for further affinity maturation as it exhibited a SEC-HPLC profile closely resembling that of the wild-type Fc (Supplementary Figure 2D available at PEDS online). To optimize the selected CD-loop amino acid residues, parsimonious mutagenesis was performed after the redefinition of the AB-loop, described in the next paragraph, to create the affinity maturation library L4: interestingly, the best clone L4_448 with an affinity of 12.4 nM, which has in 84.6% overtaken the selected pool, differed from the parental clone in five out of seven randomized amino acids.
Optimizing the AB-loop: involvement of sequences near the N-terminus
Residues 355-357 were included in the next round of randomization in addition to residues 358-361 as described above. Residue 362 was reverted to Gln as in the wild type, due to the likelihood of it forming contacts with Thr411 and Val412 in the E strand. As it is not possible to cover the theoretical diversity of a seven amino acid loop in a single yeast display library, two affinity maturation libraries were constructed in which recurring residues from the previous affinity maturation rounds were maintained: Tyr358 and Tyr361 in L3A; Tyr358, Phe360 and Tyr361 in L3B. It has also been shown that high occurrence of tyrosine in antibody-antigen contact surfaces may indicate that the side chains of these residues contribute directly to antigen binding (Fellouse et al., 2004) . Screening of L3A yielded several improved clones of similar affinity. These clones had a sequence consensus of Asp357-Tyr358-Ala359-Asn360-Tyr361 (Table II) , but differed in residues 355 and 356. All but one displayed a typical SEC-HPLC profile for Fcabs (Supplementary Figure 2E available at PEDS online). Several improved clones were Table II . Complete sequences of AB-, CD-and EF-loop and C-termini and percent occurrence among the screened improved VEGF-specific clones resulting from sorting of affinity maturation libraries L1-L5 
The sequence of the parental clone is indicated in bold letters at the top of the clones from the resulting library. For the library L2B the parental clone is not stated as pools of loops were the original material for randomization. For both libraries L3A and L3B the clone L2B_14 was the parental clone. Wt, wild-type; n.a., not applicable.
also selected from L3B, and shared identical amino acid sequences but different nucleotide sequences of synonymous mutations. This L3B_3 clone displayed an affinity to the antigen of 16 nM, higher than any of the clones isolated from L3A, and differed from the wild-type Fcab by only three amino acids at residues 359-361 within the AB-loop. Mutation of residue 359 was not intended by the design of the library but rather due to fortuitous errors in oligonucleotide synthesis.
Involvement of C-terminus in antigen binding
Starting at position 440, the eight residues at the C-terminus of an Fcab are in proximity of the putative antigen binding site and the side chains of all except Leu441 are exposed to solvent. To test if this region could also be modified to augment the binding site, the sequence of the clone L4_448 was subjected to randomization to construct the library L5. Approximately 75% of the selected clones retained antigen binding functionality when expressed as soluble Fcab and ranked using an ELISA-based binding assay. The best identified Fcab binder, CT6, had a C-terminal amino acid sequence that differed from the parental clone in all but one residue in the randomized C-terminal region (Table II) .
Characterization of CT6
CT6 could be expressed using a standard HEK293-6E mammalian expression process without any codon optimization or cell line development. Using transient transfection, an expression level of 88 mg/L was achieved as compared to 300 mg/L by the wild-type Fcab.
The protein was monomeric in SEC-HPLC profile and the retention time of 21.1 min was similar to that of 20.0 min of the wild type Fc (Fig. 4A, left panel) . Deconvolution of the DSC profile of CT6 revealed two thermal transitions at 69.9 and 75°C, where the first transition corresponds to the unfolding of the C H 2 domain and the second to the unfolding of the C H 3 domain (Fig. 4B, left panel) , respectively. In comparison, the C H 2 domain of wild-type Fcab unfolded at 70.7 and the C H 3 domain at 82.3°C, respectively. The small decreases in the melting temperature (Tm) by the engineered Fcab suggest a slight decrease in the stability of C H 3, but of negligible effect on the stability of Fcab molecule as a whole since the lowest Tm remains unchanged. The far-CD profile of CT6 was indistinguishable from that of the wild-type Fcab (Fig. 4C) . The K D to recombinant human VEGF was determined using biolayer interferometry to be~4 nM ( Fig. 5A and B) . The binding of the Fcab to recombinant VEGF was also characterized by ITC. The results showed the binding affinity to be 1.6 nM and binding stoichiometry close to 1 (0.925), suggesting bivalent binding between the two binding sites of the Fcab and the VEGF dimers (Fig. 5C ). At 25°C, the interaction resulted from a favorable gain in enthalpy (-4.019 × 10 4 ± 488.4 cal/mol), but an unfavorable loss in entropy (−2.8161 × 10 4 cal/mol). In contrast to bevacizumab, which is human-specific, CT6 also recognized the mouse homolog of VEGF albeit with a 10-fold weaker binding affinity (Fig. 5D ). The clone was specific to VEGF as it did not show any reactivity with irrelevant antigens (Supplementary Figure 4A available at PEDS online) and competed with VEGFR-2 for VEGF binding (Supplementary Figure 4B available at PEDS online). Furthermore, CT6 antagonized the VEGFstimulated proliferation of HUVEC cells in vitro (Fig. 6A ) within a range between 2760 and 276 nM. In this assay, bevacizumab could act as an inhibitor at 0.276 nM concentration (Fig. 6A) .
Characterization of bevacizumab-CT6 mAb2
A mAb 2 molecule was constructed by replacing the C H 3 domain of bevacizumab with that of CT6. The molecule (CT6/BE) was expressed transiently using HEK293-6E cells. The expression level of the mAb 2 was comparable to that of the parental mAb at 40 mg/L.
The SEC-HPLC elution profile of the mAb 2 was similar to that of the mAb, except for a slight delay in retention time (17.7 vs 16.8 min) (Fig. 4A, right panel) . Results from DSC showed that a significant difference between the mAb 2 and the parental mAb is limited to a decrease in Tm (~10°C) associated with the unfolding of the C H 3 domain, however the overall threshold of the melting temperatures is comparable between the two molecules (Fig. 4B, right panel) . Lastly, CT6/BE mAb 2 exhibited a significantly higher anti-proliferative activity in the HUVEC proliferation assay than the parental antibody (Fig. 6B) . To test developability of CT6/BE, the binding to human FcRn was tested in vitro. No difference to BE could be found for FcRn binding at pH 6.0 (K D of 4.6 × 10 −8 M was determined for BE and 3.6 × 0 −8 M for CT6/ BE) and pH-dependency of binding was retained (Supplementary Figure 5 available at PEDS online). Serum stability of the proteins was tested with mouse serum at 37°C. No significant loss of antigen binding activity could be detected after 7 days for any of the two mAbs tested.
Structural modeling and MD simulation
The model of CT6 simulated using SWISS-MODEL (Arnold et al., 2006) was very similar to the wild-type Fcab template crystal structure (PDB 1OQO). Only the part of the CD-loop containing the five inserted residues represented a significant structural difference. An ab initio approach to remodel the AB-and CD-loops of CT6 with Rosetta 3.5 and the Next-Generation Kinematic Closure (NGK) algorithm (Mandell et al., 2009; Stein and Kortemme, 2013) resulted in distinct minimum energy models. Overall the conformations of the two loops were similar to that of the wildtype in their backbone configuration which contains an α-helical secondary structure. However, the AB-loop helix of CT6 exhibited the α-helical (i +4) conformation instead of the 3 10 helix (i +3) conformation found in 1OQO. No unique low energy conformations could be obtained for the CD-loop and the C-terminal strand. Structural models with the lowest energy states from the ab initio approach were chosen for further refinement. MD simulations were performed twice for each of three selected dimeric structural coordinates (wild-type C H 3, the CT6 homology model and the CT6 ab initio loop model) for 300 ns, of which the last 200 ns of every simulation were subjected to detailed analysis. Visual trajectory inspection and secondary structure assignment using the Define Secondary Structure of Proteins (DSSP) algorithm (Kabsch and Sander, 1983 ) revealed α-helical secondary structure in the AB-and EF-loops of CT6 comparable to those in the wild-type C H 3 (Fig. 7A) . Moreover, un-and refolding of the helices in both loops could be observed. The CD-loop of CT6 did not show any β-hairpin-like motif as observable in the wild-type C H 3. Instead, it adapted flexible bend and coil configurations according to the DSSP classification. The occurrence of hydrogen bonds was determined using a geometric criterion, based on a maximal donor-acceptor distance of 0.35 nm and a maximal hydrogen-donor-acceptor angle of 30°. The results showed that Ser416 in the EF-loop of CT6 was interacting frequently with the backbone of the CD-loop and sometimes with the side chains of Asn389c (letters a-e denote the inserted residues) and Asn390. The flexibilities of the AB-and EF-loops were comparable between CT6 and the wild-type Fcab in the simulations as judged by atom-positional root-mean-square fluctuation (RMSF) values of the main-chain atoms. By contrast, the RMSF of residues in the CD-loop of CT6 exhibit higher values than that of the wildtype C H 3 (Fig. 7B) .
Trajectories of CT6 were pooled and for each mutated loop and the C-terminal strand a pairwise atom-positional root-mean-square deviation (RMSD) matrix was constructed after a pairwise leastsquares rotational and translational fit of the major β-strands of the C H 3 domain. Snapshots of backbone atoms at 40 ps intervals were subjected to RMSD matrix construction. Subsequently, matrices were clustered (Daura et al., 1999 ) using a cutoff so that 85-90% of Fig. 3 Amino acid residues of the loops of the affinity matured clones from the libraries L1-L4. Residues unchanged from the parental clone are in blue, newly introduced residues are in green, and residues imposed by the library design are in red. Bubble size indicates the proportion of the residue occurrence among the improved clones, not corrected (left) or corrected (right) for the occurrence of the clone in the selected pool. Library L2B is not presented because of its polyclonal origin, and library L5 because of the outcome of a single strongly improved clone. For library L4, inserted residues are denoted with 389a-e. all conformations were represented by the first 10 clusters. The cutoff radii used were 0.16 nm for the AB-loop, 0.24 nm for the CDloop, 0.17 nm for the EF-loop and 0.26 nm for the C-terminal strand. All 10 central structures of the AB-loop and 7 of 10 central structures of the EF-loop including the central structures of the first three most visited clusters displayed α-helical conformations. We observed a hydrophobic cluster consisting of residues Leu358, Val363, Leu365, Trp417, Phe423 and Leu441, to which the newly introduced residues Tyr414, Leu418 and sometimes Tyr443 were contributing. The central structures of the 10 most visited clusters of the CD-loop were diverse. The residues Ser383 and Asn384 appeared to extend the C-β-strand in 8 of 10 clusters. Notably, in 5 of 10 central structures (including the one of the second most visited cluster) the side chain of Phe389a was clearly orientated towards the hydrophobic domain center. The side chain of Leu389e also pointed to the center of the domain in 8 of 10 central structures. The central structures of the C-terminal strand exhibited very heterogeneous configurations without any discernible secondary structures. Fig. 7B shows graphical representations of the central structures of the 10 most visited clusters of the three mutated loops and the C-terminal strand.
Discussion
Fcab binding selections
We have designed Fcab libraries in which the three C-terminal structural loops of the C H 3 domain as well as the C-terminus are randomized, and used iterative cycles of mutagenesis and selection, combined with screening of the mutants to improve the binding affinity of an anti-VEGF Fcab. The initial clones from the naïve selection were binders of micromolar affinity resulting from the library with 10 residues randomized in the AB-and EF-loop of the C H 3 domain. Sites remote from antigen-combining region or buried within the protein could modulate antigen binding affinity indirectly and have many times been exploited for improvement of affinity and catalytic efficacy (Arkin and Wells, 1998) . Here we addressed the spatially proximal residues for binding affinity optimization. To compensate for the underrepresentation of the naïve library, we subjected the mutated residues to further parsimonious mutagenesis. This resulted in an efficient affinity improvement of~10-fold.
An improvement in the binding affinity was achieved by an insertion in the CD-loop. Such insertion has the potential to expand the binding surface created by the initial design of the Fcab, if required. For this modification pools of loops of already matured clones were isolated and shuffled with novel random sequences, as opposed to maturing a single binder. Supporting this strategy was the observation that all of the clones from the unselected library constructed in this way still retained antigen binding. Equally important was the preservation of the overall structural integrity in the high affinity clones indicated by their monomeric HPLC profiles, suggesting that the insertion site as well as the inserted loop length is well tolerated.
The AB-loop of the best binders with an insertion in the CDloop showed strong sequence consensus. Two affinity maturation libraries were constructed in which residues 355-357 were rerandomized and the initial mutation of Glu362Asn was reverted. Regarding the monomeric HPLC profiles and the AB-loop consensus of the improved clones this can be considered a viable mutagenesis strategy for binding optimization, although the sequence of the best binder was not conform to the library design.
Additional C-terminal sequence randomization further improved the affinity of antigen binding, which suggests that this region, spatially proximal to the putative binding site, provides another opportunity for improving binding interactions with the antigen without structurally impairing the molecule.
Biophysical properties of the affinity matured Fcab
In this study we were able to achieve low nanomolar VEGF binding by mutating 21 residues and inserting five residues located near the C-terminal region of the C H 3 domain. Antigen binding was enthalpy driven and accompanied with an unfavorable entropic term, which can be interpreted when considering the fact that unfavorable conformational entropy changes and loss of rotational and translational entropy were not balanced by the favorable desolvation of nonpolar surface, as observed previously for engineered binding proteins (Dogan et al., 2006) . Nevertheless, this property does not seem to be limiting for the development of high-affinity antigen binding Fc fragments. Clone CT6 expressed well, retained wild-type-like secondary structure, demonstrated a monomeric SEC-HPLC profile and did not display a significant detrimental change to its thermal stability. Together these results indicated a structure that remains compact despite of the substantial sequence mutation and insertion, which underlines the structural plasticity of the Fc scaffold for modifications. The CT6-inherent Gln418Leu mutation has previously been described to thermally stabilize C H 3 domains , possibly through hydrophobic interactions with residues Trp417 and Leu441.
The insights from molecular dynamics simulation offer supporting information on the conformational stability and local flexibility of the mutated immunoglobulin domain. Except for the insertion in the CD-loop, the RMSF values are comparable between CT6 and wild-type C H 3, which corroborates the engineering principles applied in the design of this binder.
Biological implications for inhibition of VEGF
The Fcab showed significant antagonistic activity in a VEGFdependent endothelial cell proliferation assay in vitro, albeit with a Fig. 6 Results of the HUVEC MTT proliferation assay for (A) CT6 and bevacizumab, and (B) bevacizumab and CT6-bevacizumab. Error bars indicate +/-one standard error. Squares indicate percent inhibition. Asterisk indicates a very significant difference in cell viability dependent MTT reduction (P < 0.01). Sample sizes were n = 2 for the incubation with medium alone and n = 4 for all other measurements.
lower potency than bevacizumab in the same assay. Strong inhibition of HUVEC proliferation by bevacizumab with IC 50 below 1 nM has been reported previously (Han et al., 2009; Wang et al., 2014) . Apart from weaker antigen binding, the reason for the less potent inhibition of Fcab may be that the VEGF epitope bound by CT6 only partially overlaps with the binding site of bevacizumab, which is also suggested by their different reactivity towards mouse antigen.
The K D value of CT6 towards VEGF of 4 nM is only by a factor of two higher than the equilibrium binding constant of 2.2 nM, characteristic for bevacizumab when applied to immobilized VEGF (Liang et al., 2006) , however a binding constant as low as 58 pM has been observed for VEGF binding to bevacizumab immobilized on Protein A sensor chips (Papadopoulos et al., 2012) . For the bevacizumab Fab fragment, various affinities from 1.8 nM to 20 nM have been reported (Presta et al., 1997; Chen et al., 1999) . The affinity to VEGF of the CT6 as stand-alone Fcab is markedly lower than the 1-4 pM reported for the anti-VEGF directed ankyrin-based therapeutic candidate MP0112 (Souied et al., 2014) and 25 pM of the anti-VEGF anticalin PRS-050 (Gille et al., 2016) . One cannot exclude that a more potent Fcab variant for binding to this particular epitope on VEGF can be produced. We have applied yeast display using libraries of moderate size for the maturation procedure followed by parsimonious mutagenesis to compensate for the underrepresentation in randomization. Yet not all combinations of Fig. 7 Graphical representation of CT6 from molecular dynamics simulation. (A) The central members of the 10 most visited clusters are shown in blue for ABloop, in green for CD-loop, in yellow for EF-loop and in red for C-terminus. As in the bar graph, a more intense shading indicates a higher number of structures in a cluster. (B) Arithmetic mean RMSF value over residue for the last 200 ns of each simulated species: wild-type C H 3 (black), ab initio CT6 loop model (blue) and the CT6 homology model (orange). Error bars indicate ± one standard error (n = 4). The wild-type sequence (bottom) is aligned to the CT6 sequence (top) with a gap spanning the five-residue insertion in the CD-loop of CT6. mutated stretches have been tested. To retain the structural integrity of the molecule, we have limited our binding optimization strategy to the C-terminal part of the C H 3 domain, more particularly to a subset of residues with high solvent exposure. This allowed us to use the Fcab as a building block in an existing VEGF-blocking antibody, taking advantage of a more potent cytokine inhibition. Since VEGF is known to associate with proteoglycans on cell surface (Gengrinovitch et al., 1999) , the multivalent form could also profit from an avidity effect in vivo. In spite of its very high affinity to VEGF, the anticalin PRS-050 was similar to bevacizumab in the ability to interfere with VEGF-mediated HUVEC proliferation (Gille et al., 2016) . The very potent ankyrin inhibitor exhibits a strong effect in endothelial cell sprouting assays, but the main use of this compound has been oriented to intravitreal and topical applications (Stahl et al., 2013) .
Recent developments in anti-angiogenesis therapy have been focusing on inhibiting multiple signaling pathways which could provide a potential escape mechanism from VEGF signaling blockade, such as the platelet-derived growth factor (PDGF)-fibroblast growth factor (FGF) signaling pathways (Zhao and Adjei, 2015) . Multispecific ankyrinbased binding agents that have already entered clinical testing support the idea of an increased biological efficacy due to combined cytokine inhibition (Dong et al., 2014) . So CT6 could be a valuable building block of a multispecific agent, which could potentially simultaneously inhibit multiple proangiogenic pathways to overcome resistance to a monospecific agent such as bevacizumab (Crino and Metro, 2014) .
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